zoledronic acid

(redirected from Aclasta)
Also found in: Medical.
Translations

zoledronic acid, zoledronate

n ácido zoledrónico, zoledronato (esp. Esp)
References in periodicals archive ?
syringe 0200685 Ikametin 150 mg 0,200,862 Licobondrat 150 mg film-coated tablets 0,166,418 Osagrand 150 mg 0,166,412 Osagrand 3 mg / 3 ml risedronic acid SKL code: 0177298 Melenor 35 mg 0,129,225 Risedronate Teva 35 mg 0,105,178 Risendros 35 mg 0,187,318 Rismyl 35 mg 0,187,849 Tevanel 35 mg zoledronic acid SKL code: 0027103 Aclasta 5 mg alendronic acid and colecalciferol sukl code: 0196943 alendronic acid / Vitamin D3 Teva 70 mg / 0.
Alkaline phosphatase U/L Months 0 3 6 9 12 15 18 Calcitonin 15000 1400 1345 Aclasta 1345 500 215 170 125 Alkaline 80 80 80 80 80 80 80 Phosphatase (normal range) Note: Table made from line graph.
Mansoor Jaffari has the products Voltral ,Caflam, Ternelin, Aclasta and Miacalcic.
Primary care nurses at the Golden Bay Medical Centre in Takaka have been doing aclasta infusion for more than two years.
Zometa, given as an infusion, also is sold at a lower dose under the name Reclast or Aclasta to treat osteoporosis.
Bisphosphonates include Aclasta, Actonel, Aredia, Bondronat, Boniva, Didronel, Fosamax, Fosavance, Reclast, Skelid and Zometa.
18 October 2010 - Swiss Novartis (VTX: NOVN) said on Saturday that new six-year study results have confirmed the long-term efficacy and safety profile of Aclasta, taken once a year, for the treatment of osteoporosis in post-menopausal women.
Higher sales are also seen for such newer products as Lucentis for macular degeneration and Aclasta for osteoporosis.
The most recent is Aclasta, the first annual treatment for post-menopausal women, which reduced risk of hip fractures by 41 per cent in trials.
A diferencia de otros tratamientos con bisfosfonatos, en los que las mujeres toman dosis diarias, semanales o mensuales para su osteoporosis posmenopausica, Aclasta se adm inistra como una infusion de 15 minutos solo una vez al ano.
For example, Tasigna, a new cancer drug, and Aclasta, a once-yearly infusion for women with osteoporosis, have been submitted for regulatory approval in both the United States and Europe.